Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The sudden emergence of coronavirus disease 2019 (COVID-19) caused significant disruptions to health care delivery. To offset the limited ability to see patients in person, many eye care providers rapidly implemented telehealth services to assess patients remotely, provide health education, and manage eye conditions, including glaucoma.1–3 This study evaluated factors that predict which patients with open-angle glaucoma utilized telehealth services and successfully returned for in-person follow-up care after the outbreak of COVID-19.

Included in the study were 1843 patients with open-angle glaucoma who were seen at an outpatient ophthalmology clinic in 2019 and were due for a return examination in the period after the recognized outbreak of COVID-19 on March 15, 2020, through December 31, 2020. Telehealth was offered to any patient who could not be seen in the clinic because of the prevailing public health conditions for both scheduled and problem visits, as appropriate. Services delivered by telehealth included a check of symptoms, refilling of any medication, health education, and assuring future follow-up. Logistic regression was employed to identify factors associated with telehealth utilization and in-person follow-up. All tests were 2-sided, and P values of < 0.05 were considered significant (SPSS Statistics 28.0, IBM Corp.).

Telehealth encounters were completed by 823 patients (45%). Most of those encounters were conducted by ophthalmologists (95%) via the telephone (99%). Patients who accessed telehealth did not show any differences in age, sex, race, or disease severity (Table S1, available at www.ophthalmologyglaucoma.org). Patients insured by Medicare (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.0–1.9; P = 0.049), who had more severe visual impairment in their worse eye (OR, 1.2; 95% CI, 1.0–1.5; P = 0.031), or who had up-to-date visual field testing (OR, 1.3; 95% CI, 1.1–1.6; P = 0.004) or disc imaging (OR, 1.6; 95% CI, 1.3–1.9; P < 0.001) were more likely to access care by means of telehealth (Table S2, available at www.ophthalmologyglaucoma.org).

In-person follow-up visits were completed by 1249 (68%) patients. Most of these evaluations (98%) were conducted by ophthalmologists. The demographic characteristics are summarized in Table S3 (available at www.ophthalmologyglaucoma.org). Patients with larger cup-to-disc ratios (OR, 2.4; 95% CI, 1.3–4.3; P = 0.003), insured by Medicare (OR, 1.8; 95% CI, 1.3–2.6; P < 0.001), or who had a prior trabeculectomy (OR, 1.9; 95% CI, 1.2–3.0; P = 0.009) or trabeculoplasty (OR, 1.6; 95% CI, 1.1–2.3; P = 0.011) were more likely to complete an in-person follow-up. Older patients (OR, 0.98; 95% CI, 0.97–1.0; P = 0.009), those with prior cyclophotocoagulation (OR, 0.52; 95% CI, 0.28–0.97; P = 0.039), or those who had recent visual field testing (OR, 0.23; 95% CI, 0.18–0.28; P < 0.001) or disc imaging (OR, 0.54; 95% CI, 0.43–0.67; P < 0.001) were less likely to complete an in-person follow-up (Table S2).

To our knowledge, this study is among the first to explore how eye care was delivered to patients with glaucoma after the recognized outbreak of COVID-19.1–3 We determined that patients with more severe open-angle glaucoma, as indicated by a larger cup-to-disc ratio, or a prior history of trabeculectomy or trabeculoplasty were more likely to return for in-person care. Notably, older patients were less likely to return for in-person evaluations. One possible explanation for this is that contracting COVID-19 posed a disproportionate risk to older individuals. Additionally, patients who had undergone cyclophotocoagulation were also less likely to return. This procedure is predominantly used to manage end-stage glaucoma. Although many of these individuals may have been at risk of vision loss, they may have had relatively less to gain from in-person evaluation and management under the circumstances of the COVID-19 pandemic.

Patients with glaucoma are known to be at risk of vision loss from loss to follow-up. The outbreak of COVID-19 exacerbated this problem. Before the COVID-19 pandemic, telehealth was used to reach patients with glaucoma in remote or underserved communities, to provide additional time for counseling, or to improve adherence.4–7 Although most traditional examination elements are lacking in telehealth encounters, important clinical services and health education can be delivered to reduce the likelihood of experiencing lapses in glaucoma care.

In our study, we found that patients who had recent ancillary testing had an increased utilization rate of telehealth but a lower rate of completing in-person visits. It may be that providers relied on recent visual field testing or optic nerve imaging as an objective way to evaluate the state of glaucoma severity or to assess the risk of its progression. In contrast, those overdue for glaucoma testing would have been prioritized by their providers to return for in-person visits. From the data available, we cannot determine a precise set of criteria governing these management decisions. However, the fact that patients with more severe glaucoma were more likely to receive an in-person evaluation suggests that patients at greatest risk of further vision loss were able to access eye care services when needed throughout the pandemic.

The limitations of our study include its retrospective nature and its restriction to a suburban population from a single academic center, potentially impacting the generalizability of our findings. The data available did not allow us to assess treatment history that was not captured by Current Procedural Terminology codes, such as use of glaucoma medications, or provide information on which patients were offered (or refused) telehealth services. The lack of specificity of the International Statistical Classification of Diseases, Tenth Revision, coding for glaucoma in our sample precluded us from using these data to stage the disease. Additionally, clinical outcomes between the groups were not evaluated, given the limited study interval. Finally, changing state-specific guidelines, and the expansion of reimbursement for telehealth services by Medicare, could have potentially affected patients’ eligibility or their likelihood to utilize virtual services. The continued use of telehealth on a large scale will likely depend on the extent of coverage for such services, which vary greatly by region.

Our study demonstrates that most patients with open-angle glaucoma who were due for a return evaluation after the outbreak of COVID-19 were able to be cared for through a combination of in-person care and telehealth consultations (Figure 1). This is a very
encouraging finding because it demonstrates how telehealth can potentially be used to augment the delivery of care to patients with glaucoma beyond the COVID-19 state of emergency. Future studies should seek to determine whether the continued use of telehealth services, especially when combined with visits for ancillary testing, can reduce health care costs and improve patient outcomes.

**ALEXANDER HUTHER, MD**\(^1,2\)

**SHIYOUNG ROH, MD**\(^1,2\)

**DAVID J. RAMSEY, MD, PhD**\(^1,2\)

\(^1\)Department of Ophthalmology, Lahey Hospital & Medical Center, Peabody, Massachusetts; \(^2\)Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts

Presented at the 784th Meeting of The New England Ophthalmological Society, May 14, 2021, Boston, Massachusetts.

Disclosures: All authors have completed and submitted the ICMJE disclosures form. The authors made the following disclosures: D.J.R.: Financial support — Harry N. Lee Family Chair in Innovation at the Lahey Hospital & Medical Center, Beth Israel Lahey Health.

HUMAN SUBJECTS: The research followed the tenets of the Declaration of Helsinki and was approved by institutional review board of the Lahey Hospital & Medical Center (Burlington, MA). Information was gathered and secured in compliance with the Health Insurance Portability and Accountability Act. The requirement for informed consent was waived.

No animal subjects were used in this study.

Author Contributions:

Conception and design: Ramsey, Roh, Huther

Data collection: Ramsey, Roh, Huther

Analysis and interpretation: Ramsey, Roh, Huther

Obtained funding: Ramsey

Study was performed as part of regular employment duties at the Lahey Hospital & Medical Center, Beth Israel Lahey Health. No additional funding was provided.

Overall responsibility: Ramsey, Roh, Huther

Abbreviations and Acronyms:

CI = confidence interval; COVID-19 = coronavirus disease 2019; OR = odds ratio.

Keywords:

Adherence, Electronic health record, Glaucoma, Medical informatics, Quality improvement.

Correspondence: David J. Ramsey MD, PhD, MPH, Lahey Medical Center, 1 Essex Center Drive, Peabody, MA 01960. E-mail: david.j.ramsey@lahey.org.

**References**

1. Vinod K, Sidoti PA. Glaucoma care during the coronavirus disease 2019 pandemic. *Curr Opin Ophthalmol*. 2021;32:75–82.
2. Robbins CC, Anjum S, Alweikat AM, et al. An initiative to improve follow-up of patients with glaucoma. *Ophthalmol Sci*. 2021;1(4):100059.
3. Aziz K, Moon JY, Parikh R, et al. Association of patient characteristics with delivery ofophthalmic telemedicine during the COVID-19 pandemic. *JAMA Ophthalmol*. 2021;139:1174–1182.
4. Thomas SM, Jeyaraman MM, Hodge WG, et al. The effectiveness of teleglaucoma versus in-patient examination for glaucoma screening: a systematic review and meta-analysis. *PLoS One*. 2014;9:e113779.

5. Hark LA, Katz LJ, Myers JS, et al. Philadelphia telemedicine glaucoma detection and follow-up study: methods and screening results. *Am J Ophthalmol*. 2017;181:114–124.

6. Odden JL, Khanna CL, Choo CM, et al. Telemedicine in long-term care of glaucoma patients. *J Telemed Telecare*. 2020;26:92–99.

7. Gan K, Liu Y, Stagg B, et al. Telemedicine for glaucoma: guidelines and recommendations. *Telemed J E Health*. 2020;26:551–555.